Neuropsychiatric disorders are one of the main challenges of human medicine with epilepsy being one of the most common serious disorders of the brain. Increasing evidence suggest neuropeptides, particularly the opioids, play an important role in epilepsy. However, little is known about the mechanisms of the endogenous opioid system in epileptogenesis and epilepsy. Therefore, we investigated the role of endogenous prodynorphinderived peptides in epileptogenesis, acute seizure behaviour and epilepsy in prodynorphin-deficient mice. Compared with wild-type littermates, prodynorphin knockout mice displayed a significantly reduced seizure threshold as assessed by tail-vein infusion of the GABA A antagonist pentylenetetrazole. This phenotype could be entirely rescued by the kappa receptor-specific agonist U-50488, but not by the mu receptor-specific agonist DAMGO.The delta-specific agonist SNC80 decreased seizure threshold in both genotypes, wild-type and knockout. Pre-treatment with the kappa selective antagonist GNTI completely blocked the rescue effect of U-50488. Consistent with the reduced seizure threshold, prodynorphin knockout mice showed faster seizure onset and a prolonged time of seizure activity after intracisternal injection of kainic acid.Three weeks after local injection of kainic acid into the stratum radiatum CA1 of the dorsal hippocampus, prodynorphin knockout mice displayed an increased extent of granule cell layer dispersion and neuronal loss along the rostrocaudal axis of the ipsi-and partially also of the contralateral hippocampus. In the classical pentylenetetrazole kindling model, dynorphindeficient mice showed significantly faster kindling progression with six out of eight animals displaying clonic seizures, while none of the nine wild-types exceeded rating 3 (forelimb clonus). Taken together, our data strongly support a critical role for dynorphin in the regulation of hippocampal excitability, indicating an anticonvulsant role of kappa opioid receptors, thereby providing a potential target for antiepileptic drugs.
Introduction
With a prevalence of 1-2% epilepsies are one of the most frequent neurological diseases (McNamara, 1999) . According to the WHO, 50 million people are affected world-wide, thereby accounting for 1% of global burden of disease (WHO, 2005) . About 70% of all epilepsy patients suffer from focal seizures, arising from a distinct brain region. Mesial temporal lobe epilepsy (mTLE) is, to our present knowledge, the most frequent type of epilepsy. treatment. Thus, new therapeutical strategies are needed, and might be found in the field of neuropeptides.
The number of studies supporting the importance of neuropeptides in epileptogenesis and epilepsy are increasing. Since the early 1980s, there is evidence that opioids, namely dynorphin, act as modulators of neuronal excitability in vitro (Henriksen et al., 1982; Siggins et al., 1986; Wagner et al., 1993; Weisskopf et al., 1993) . Like the other classical opioid peptides, dynorphin exerts its actions through three opioid receptors named kappa (KOR), mu (MOR) and delta (DOR), with highest affinity to KOR (Chavkin et al., 1982) . However, since the 1990s, also nonopioid effects of dynorphin (defined through insensitivity to naloxone) were reported, mainly depending on direct actions on NMDA receptors (for review see Wollemann and Benyhe, 2004) . Potentiation of endogenous anti-ictal mechanisms by opioids was shown in animal models of epilepsy (Tortella, 1988; Tortella and Long, 1988; Terman et al., 2000) , including viral-induced seizures (Solbrig et al., 2006) , and low dynorphin expression in man is associated with increased epilepsy vulnerability (Stogmann et al., 2002; Gambardella et al., 2003) . Mostly, these effects were attributed to KOR function. On the other hand, KORs are rare in the hippocampus (Maggi et al., 1989; DePaoli et al., 1994; Gackenheimer et al., 2005) , which represents the central element of mTLE. In addition, application of KOR-specific agonists and antagonists does neither address the involvement of potential proconvulsant effects mediated through MOR located on GABAergic interneurons nor the induction of seizures by DOR agonists nor non-opioid effects on NMDA receptor functions.
In fact, till now very little information is available on the role of endogenous dynorphin in epileptogenesis and seizure behaviour. It is still controversial, whether the net effect of prodynorphin-derived peptides acting on DOR, KOR, MOR and/or NMDA receptors is pro-or anticonvulsant. On the other hand, we need detailed knowledge of the physiological and pathophysiological role of the opioid system to develop strategies for novel treatments. To address these issues, we investigated prodynorphindeficient mice in animal models of epileptogenesis and acute seizures.
Material and methods

Targeting vector construction and gene disruption
The coding sequence for the transactivator of the Tet-on system (rTetR) was introduced directly after the ATG of the prodynorphin gene using an XbaI site, which was mutated into the prodynorphin sequence by means of polymerase chain reaction (PCR) (mutating reverse primer: 5 0 -GCTCTAGACATTCTGA CTCACTTGTTTG-3 0 ). The sequence for the transactivator responsive element (TRE) was placed against the prodynorphin reading direction, driving Cre-recombinase expression. In the same direction, we placed a loxP site flanked cassette containing neomycin and zeocin resistance genes. 
Real-time polymerase chain reaction (RT-PCR)
RT-PCR was performed on cDNA gained from entire hippocampal mRNA extracts. The mRNA was isolated using oligo-dT primers covalently coupled to magnetic beads (DynalBiotech, Hamburg, Germany) and transcribed to cDNA using Superscript II reverse transcriptase TM and oligo(dT)12-18 primers (both Invitrogen, Lofer, Austria) using standard protocols. Taqman primer sets for the amplification of DOR, KOR and MOR (Applied Biosystems # Mn00443063_m1; Mn00440561_m1; Mn01188089_m1, respectively) and the mouse TATA box binding protein (mTBP489f: 5 0 -ACTTCGTGCAAGAAATGCTGAA-3 0 ; mTBP564r: 5 0 -TGTCCGTGGCTCTCTTATTCTCA-3 0 ; mTBP Probe: 5 0 -TCCCAAGCGATTTGCTGCAGTCATC-3 0 ) cDNAs as internal standard were used. Amplification was carried out on ABI Prism 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) using Taqman Universal PCR Mastermix (Applied Biosystems) according to the manufacturer's instructions. Primers and probes were used at a final concentration of 800 nM and 150 nM respectively. Reactions were carried out in optical 96-well fast reaction plates (Applied Biosystems) in triplicate with 11 ml reaction volume containing a total of 3 ng of reverse-transcribed mRNA. Data are given as mean dCt of the three replicates calculated from receptor cDNA and respective mTBP cDNA amplification curves.
Seizure threshold
Seizure threshold was determined by pentylenetetrazole (PTZ) tailvein infusion on freely moving animals at a rate of 100 ml/min (100 mg/ml PTZ in saline, pH 7.4). Infusion was stopped when animals displayed generalized clonic seizures. Animals were immediately anaesthetized using increasing carbon dioxide concentrations and killed by cervical displacement. The seizure threshold dose was calculated from the infused volume in relation to body weight. Results from tail-vein infusion were verified by intraperitoneal injection of a fixed dose of 30 mg PTZ/kg body weight. Animals were observed and video-tracked for 20 min after treatment and the severity of seizures was rated: no response ¼ 0; immobility ¼ 1; myoclonic jerks ¼ 2; forelimb clonus and/or Straub tail ¼ 3; generalized clonic seizure ¼ 4; clonic seizures with jumping and running ¼ 5; death ¼ 6.
Opioid receptor pharmacology
The KOR agonist trans-(AE)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide hydrochloride (U-50488), the KOR antagonist 5 0 -guanidinyl-17-(cyclopropylmethyl)-6,7-dehydro-4,5-epoxy-3,14-dihydroxy-6,7-2 0 ,3
4 , Gly-ol]-enkephalin (DAMGO) were purchased from Tocris Cookson. KOR and MOR ligands were dissolved in saline and pH was adjusted to 7.2. SNC80 was dissolved in 1 Eq HCl. U-50488 (20 mg/kg) and SNC80 (2 mg/kg) were applied i.p. 30 and 60 min before testing, respectively. GNTI (3 nmol) and DAMGO (2 nmol) were given intracisternally under mild sevofluorane anaesthesia 20 h and 30 min before testing, respectively. Drug doses and application times were chosen according to recent studies in mice (Yokoyama et al., 1992; Jewett et al., 2001; Khavandgar et al., 2002; Manocha et al., 2003; Solbrig et al., 2006) . GNTI was preferred over nor-binaltorphimine (nor-BNI) for its higher KOR selectivity and antagonist potency (Jones and Portoghese, 2000) .
Seizure onset and duration
Delay until seizure onset and duration of clonic seizure activity was analysed in the kainic acid (KA) model. KA (0.7 mg in 3.5 ml saline, pH ¼ 7.2) was injected intracisternally under very mild sevofluorane anaesthesia. Animals were observed for a minimum of 60 or 10 min after the last clonic seizures. Subsequently, animals were immediately anaesthetized using increasing carbon dioxide concentrations and killed by cervical displacement. Delay time until the first clonus and the timespan from the beginning of the first to the end of the last clonic seizures was measured from video recordings.
Intrahippocampal injections of KA
To study neuronal degeneration and hippocampal reorganization, KA was injected into the dorsal hippocampus of deeply anaesthetized (initial: Ketasol 2 mg/kg, maintenance: inhalation of sevofluorane) mice (Bouilleret et al., 1999) . Mice were immobilized in a stereotaxic instrument (David Kopf Instruments, Tujunga, CA) with the nose bar adjusted to equal heights of lambda and bregma. Coordinates from bregma (1.8 mm anterior; 1.6 mm lateral and 1.8 mm below skull) were chosen to target the stratum radiatum of CA1 in the right dorsal hippocampus (Paxinos and Franklin, 2001) . KA (0.2 mg in 50 nl saline, pH 7.2) was applied with a 1 ml Hamilton syringe over a period of 2 min. The needle was kept in place for 5 min and retracted stepwise (0.3 mm/min) to minimize backflux. Animals were killed 3 weeks after KA injection by an overdose of thiopental (150 mg/kg) and brains were fixed by transcardial perfusion with 4% paraformaldehyde.
PTZ kindling
Two groups of mice (Dyn À/À and Dyn
) received up to 16 i.p. injections of 20 mg/kg PTZ over 5 weeks (Monday, Wednesday, Friday). The PTZ dose was established in a pre-experiment on wild-type mice. Animals were observed and video-tracked for 20 min after each treatment, and the severity of seizures was rated as described for the fixed PTZ dose injection. Animals exposing three subsequent rating 4 seizures were stated fully kindled, and received no further injections. After the last kindling session, animals were anaesthetized using increasing carbon dioxide concentrations and killed by cervical displacement.
Histology and cell counts
In situ hybridization was performed on 20 mm sections of fresh frozen tissue applying a 35 S--dATP-labelled DNA oligonucleotide (5 0 -GTTCTCCTGGGACCGCGTCACC ACCTTGAACTGACGCCG CAG -3 0 ) complementary to prodynorphin mRNA as published recently (Lin et al., 2006) . For immunocytochemistry and Nissl staining, the entire hippocampal region of paraformaldehyde-fixed tissue (Paxinos and Franklin, 2001 ) was cut to 40 mm free-floating sections. Series containing every 6th section were stained applying specific antibodies for prosomatostatin, chromogranin B, neuropeptide Y or dynorphin A using a horseradish peroxidase conjugated secondary antibody and 3,3 0 -diaminobenzidine for detection (Schwarzer et al., 1996 (Schwarzer et al., , 2001 . One series of sections were used for Nissl staining (Paxinos and Franklin, 2001) . Cell counts and measurement of granule cell layer (GCL) area were done from sections of the dorsal hippocampus, assigned to levels from 1.3 to 2.7 mm from bregma according to Paxinos and Franklin (2001) . Sections from 4 to 6 brains were evaluated for each level and the mean value taken for stereological and statistical analysis. For untreated animals, values for both hippocampi were averaged. Somatostatin immunoreactive (SST-ir) neurons were counted in the entire hippocampal subfields of the hilus, CA1 and CA3, respectively. Cell numbers of principal cell layers (CA1, CA3a, CA3b, CA3c) were assessed over a length of 125 mm covering the whole width of the layer. Specific areas counted are indicated in Fig. 3B . Granule cell dispersion was evaluated from photomicrographs through measurement of the area of the entire GCL.
Statistical analysis
For seizure threshold, pathological and pharmacological analyses, ANOVA with post hoc Bonferroni test was applied. For stereological analyses paired Student's t-test was used for comparison of genotypes at each level of the rostro-caudal axis. For RT-PCR, seizure onset and duration, unpaired Student's t-test was used for the comparison of wild-type and knockout animals. In the kindling experiment, and after injection of fixed PTZ doses, the 2 test was used to compare frequencies of seizure ratings observed in wild-type and knockout mice.
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Results
Generation of germ-line prodynorphin knockout mice
A targeting vector for the prodynorphin gene was designed and generated, which allowed the replacement of the coding sequence of the prodynorphin gene by a construct expressing Cre-recombinase under the control of the Tet-on system ( Supplementary Fig. 1A ).
Absence of prodynorphin coding sequence in homozygote Dyn À/À mice was confirmed by Southern blot analysis employing a prodynorphin gene sequence-specific DNA fragments and PCR ( Supplementary Fig. 1B and C, respectively).
To confirm that our construct provided entire loss of prodynorphin mRNA and protein, we performed in situ hybridization and immunocytochemistry experiments on brain slices from wild-type and knockout animals. As shown in Fig. 1A , wild-type mice showed significant expression of prodynorphin mRNA in the striatum, hypothalamus and hippocampus, whereas no signal was obtained in knockout animals. Wild-type mice showed significant dynorphin A immunoreactivity in nuclei also expressing prodynorphin mRNA, while knockout animals displayed no specific labelling ( Supplementary Fig. 1D ). Although the endogenous ligand with the highest affinity for KOR was lacking in Dyn À/À mice ( Supplementary  Fig. 1E ), no obvious difference in KOR immunoreactivity was evident comparing the staining pattern in sections from the dorsal or ventral hippocampus (Fig. 1B) .
Data obtained from RT-PCR show that DOR cDNA was expressed about 10 and 15 times more than KOR and MOR cDNAs, respectively (Fig. 1A) . Changes in cDNA levels were minor for DOR and KOR. MOR cDNA was increased by $40% (P ¼ 0.0206; Fig. 1A ) in Dyn À/À mice.
Seizure threshold
Seizure threshold was assessed by tail-vein infusion of PTZ (1 mg/min). Wild-type mice showed clonic seizures at 39.1 AE 0.96 mg PTZ/kg (n ¼ 9) body weight. Prodynorphin knockouts displayed a significantly (P50.05) reduced seizure threshold of 32.7 AE 1.17 mg PTZ/kg (n ¼ 6) ( Fig. 2A) . Heterozygous mice displayed an intermediate seizure threshold (36.7 AE 1.93; n ¼ 8). A similar seizure threshold as in Dyn À/À was measured in wild-type mice pre-treated with the KOR-specific antagonist GNTI (3 nmol i.c.) 20 h before PTZ infusion (31.4 AE 1.25; n ¼ 6). The reduced seizure threshold of Dyn À/À mice could be fully rescued by pretreatment with the KOR agonist U-50488 (20 mg/kg; 30 min before PTZ), yielding a threshold of 41.5 AE 1.77 (n ¼ 6). This rescue effect was completely reversed by treating the mice with GNTI (3 nmol i.c.) 20 h before agonist application (33.1 AE 1.43 mg PTZ/kg; n ¼ 6; Fig. 1B) . Treatment of Dyn À/À mice with the DOR selective agonist SNC80 (2 mg/kg, i.p.) 1 h before PTZ infusion resulted in a markedly reduced seizure threshold of 17.5 AE 1.22 mg PTZ/kg (n ¼ 6) (Fig. 1C) . Noteworthy, none of these animals showed any signs of spontaneous seizure activity. To investigate potential compensatory changes on the level of DOR, we included a group of Dyn þ/þ mice treated with SNC80 prior to PTZ infusion, yielding a seizure threshold of 23.8 AE 1.01 mg PTZ/kg (n ¼ 5; Fig. 1C ). Treatment of Dyn À/À mice with the MOR selective agonist DAMGO 30 min before infusion resulted in an unchanged seizure threshold of 32.5 AE 1.68 mg PTZ/kg (n ¼ 6; Fig. 1C ). Efficiency of drug treatment was controlled through animal behaviour. Mice receiving the KOR agonist were very calm, displaying typical drowsiness. GNTI entirely rescued this behavioural effect when given 20 h before U-50488. Animals treated with the KOR antagonist alone were highly alert and displayed some anxious like behaviour. Injection of SNC80 did not change behaviour dramatically; however, animals appeared more alert. DAMGO induced significant effects on mouse behaviour, including the MOR agonist typical 'Straub-tail', stiff hanging when picked up at the tail and hypoalgesia. Intraperitoneal injection of a fixed dose of 30 mg PTZ/kg body weight resulted in a significantly different seizure response. Wild-type mice showed seizure severity scores of 2 (myoclonic jerks; n ¼ 5) and 3 (forelimb clonus; n ¼ 2) with only one animal displaying a clonic seizure (rating 4). In contrast, Dyn À/À mice reached a significantly (P50.01; 2 test) higher seizure rating with three mice rated 3 and five animals displaying clonic seizures.
Seizure onset and duration
Seizure onset and duration was examined by intracisternal injection of 0.7 mg KA. In wild-type mice, clonic seizures were observed after 277 AE 45 s (n ¼ 5) and lasted for mice and wild-type mice treated with GNTI (Dyn þ/þ þ GNTI) did not differ. The DOR specific agonist SNC80 markedly reduced seizure threshold in both Dyn À/À and Dyn þ/þ mice to a similar extend (panel C). The MOR specific agonist DAMGO did not influence the seizure threshold of Dyn À/À mice, although mice displayed a broad behavioural spectrum induced by MOR agonists. Our data clearly indicate that the main anticonvulsant activity of dynorphin is mediate by KOR. Panel D depicts the differences in acute seizure behaviour induced by ic injection of kainic acid. The left part shows the delay of seizure onset, while the right part illustrates the duration from the first to the last clonic seizure observed. *p50.05; **p50.01; ***p50.001 versus untreated genotype matched control; ¥¥ p50.01 versus Dyn Fig. 1D ). Animals injected with the same volume of saline recovered within a few seconds from anaesthesia and did not show any signs of seizure activity.
Seizure-related neurodegeneration and hippocampal reorganization
Potential neuroprotective effects of dynorphin were investigated in a model described as 'non-convulsant' status epilepticus induced by unilateral injection of 0.2 mg KA into the stratum radiatum of area CA1 of the dorsal hippocampus. In our hands, most of the treated mice showed myoclonic jerks and forelimb cloni when observed for gross behaviour 1 h and 1, 2 and 3 weeks after treatment. In both groups of animals, hippocampal neurodegeneration was prominent in CA1 and CA3c principal neurons of the ipsilateral dorsal hippocampus (Table 1 , Figs 3 and 4). This goes in line with reduced numbers of SST-ir interneurons in these areas. Induction of neuropeptide Y (NPY) expression in mossy fibres of both hippocampi was observed in all KA-treated animals. Pathological changes were accompanied by sprouting of mossy fibres and a significant drop in immunoreactivity for ChB and NPY in the terminal field of mossy fibres as compared with the contralateral side (Fig. 4) . Dyn À/À mice displayed a significantly broader extent of granule cell dispersion along the rostrocaudal axis of the ipsilateral hippocampus (P ¼ 0.0121 versus WT; n ¼ 4-6 per level; Table 1 , Figs 3 and 4), but did not differ from Dyn þ/þ mice in maximal area covered by the GCL at the level of the injection site. The same holds true for the loss of Nissl stained and SST-ir neurons in the hilus (P ¼ 0.0077 versus WT; n ¼ 4-6 per level) and in area CA1 (P ¼ 0.0033 versus WT; n ¼ 4-6 per level). In addition, Dyn À/À mice showed markedly reduced SST-ir interneurons in the ipsilateral area CA3, while these neurons were still observed in wild-type mice (P ¼ 0.0021 versus WT; n ¼ 4-6 per level). Reduction of SST-ir interneurons in area CA1 (P50.0001 versus WT; n ¼ 4-6 per level) as well as neurodegeneration of CA1 pyramidal cells (P ¼ 0.0053 versus WT; n ¼ 4-6 per level), accompanied by reduced NPY immunoreactivity in this subfield was observed in the contralateral hippocampus of Dyn À/À mice, but not in Dyn þ/þ mice (Table 1 , Figs 3 and 4) . Noteworthy, Dyn À/À mice displayed a significantly stronger reduction of Nissl stained neurons in the contralateral hilus (P ¼ 0.0133 versus WT; n ¼ 4-6 per level), while no reduction of SST-ir neurons was observed. No difference was observed in the reduction of SST-ir neurons in contralateral area CA3. In the ipsilateral dorsal hippocampus, marked changes in patterns of immunoreactivity for ChB and NPY were evident (Fig. 4) . 
PTZ kindling
Classical PTZ kindling progression was investigated over a period of 5 weeks ( Table 2 ). The kindling dose was established in pre-experiments. At a dose of 20 mg/kg wild-type mice rarely exceeded rating 2 seizures with five out of nine mice displaying rating 3 seizures once or twice within the time investigated (Table 2) . On the other hand, prodynorphin-deficient mice showed clonic seizures beginning from injection 10, with six out of eight mice displaying at least one clonic seizure within 5 weeks. Furthermore, the frequency of mice exhibiting higher seizure scores in the knockout group was significantly increased from the fifth injection (Table 2 ). The kindling progression in Dyn À/À mice was similar to that observed in five wild-type mice injected with 25 mg PTZ/kg in dosefinding experiments (data not shown).
Discussion
Our data show decreased seizure threshold in the PTZ tail-vein infusion model and increased seizure activity in the acute KA model in prodynorphin-deficient mice. This is accompanied by increased neuropathological and morphological changes in a chronic epilepsy model. In line with this, kindling progression is significantly faster in Dyn À/À mice as in wild-type littermates in the classical PTZ kindling model. Thus we propose an anticonvulsant action of endogenous prodynorphin-derived peptides. Application of DOR-, KOR-and MOR-specific agonists and antagonists clearly identifies KOR as the mediators of these effects.
The correctness of the prodynorphin knockout became evident from the lack of prodynorphin mRNA and dynorphin A immunoreactivity. Potential compensatory changes in the expression of opioid receptor mRNAs in the hippocampus are restricted to MOR, which is increased by about 40% in our Dyn À/À mice. In contrast, no increase in MOR binding was observed in other Dyn À/À mice (Clarke et al., 2003) . However, MOR receptor mRNA is expressed at low levels, and even at an elevated expression level, no influence of the MOR agonist on the seizure threshold in the PTZ tail-vein infusion model is detectable. The inference of no significant alteration in DOR functions in relation to seizure threshold is supported by the finding of a comparable reduction in Dyn À/À and Dyn þ/þ mice by the DOR normal type agonist SNC80. Unchanged KOR expression and distribution becomes evident from RT-PCR and immunocytochemistry. Normal functioning of these receptors is suggested by the full reversibility of the KOR agonist U-50488 action through the KOR antagonists GNTI.
Although there is increasing evidence for anti-ictal functions of prodynorphin-derived peptides (Seyfried and Glaser, 1985; Siggins et al., 1986; Tortella, 1988; Tortella and Long, 1988; Kai et al., 1998; Stogmann et al., 2002; Solbrig and Koob, 2004; Solbrig et al., 2006) , several questions could not be answered by pharmacological approaches. These open questions are mostly related to activation of DOR and MOR, but also to direct interactions of endogenous dynorphin with NMDA receptors. Thus, application of DOR agonists causes seizures (Comer et al., 1993) , on the other hand the anticonvulsant action of components within the cerebrospinal fluid of rats after seizures was inhibited by the addition of DOR antagonists (Tortella and Long, 1988) . Dynorphin may inhibit the function of GABAergic interneurons through activation of MOR and KOR. The resulting inhibition of GABA release would facilitate seizures, on the other hand, desynchronization of interneurons might be beneficial in epilepsy Endogenous dynorphin in epileptogenesis and epilepsy Brain (2007), 130, 1017^1028 (Aradi et al., 2002) . Reports of dynorphin actions on NMDA receptors are also controversial. While Kanemitsu et al. (2003) suggested pH dependent inhibition of NMDA receptors, others propose stimulatory activities of dynorphin on NMDA responses (Caudle and Isaac, 1988; Shukla et al., 1997; Woods et al., 2006) . Thus, the overall effect of endogenous prodynorphin-derived peptides was still controversial. We now showed anticonvulsant and neuroprotective functions of endogenous prodynorphin derived peptides in different models of epileptogenesis, acute seizures and chronic epilepsy. In addition, our data clearly indicate that anticonvulsant actions of the endogenous prodynorphin-derived peptides are predominantly mediated via KOR. Thus, decrease in seizure threshold observed in Dyn À/À mice could be completely rescued by the specific KOR agonist U-50488, but not by the MOR-specific agonist DAMGO. MOR are supposed to be expressed almost exclusively on specific subgroups of GABAergic interneurons in area CA1 Milner, 1999, 2002) . Noteworthy, the DAMGO dose and time interval to infusion used in our study was effective in reducing electrically induced seizures in C57Bl/6 mice (Yokoyama et al., 1992) . However, their findings stand in contradiction to results obtained in other groups. Thus, activation of MOR inhibited IPSPs and facilitated the propagation of excitatory activity in principal cells of slice preparations obtained from rat hippocampus. On the other hand, this facilitation was prevented by GABA A receptor antagonists like bicuculline (McQuiston and Saggau, 2003) . Thus, the functions of MOR activation remain contradictive and have no influence in our model applying the GABA A receptor antagonist PTZ.
The DOR-specific agonist SNC80 by itself decreased the seizure threshold. Early works suggest disinhibition of principal neurons in CA1 and CA3 due to inhibition of inhibitory interneurons as main cause for the proconvulsant effects of endorphins and enkephalins acting via DOR (Siggins et al., 1986) . This may depend on the modulation of potassium and hyperpolarization-activated cation currents (Svoboda and Lupica, 1998) . A more recent study showed that the proconvulsant effect of DOR agonists depends on the activation of constitutive NO synthase (Khavandgar et al., 2002) . DOR activation may also directly influence glutamatergic neurotransmission. Thus, DOR activation modulates the functions of voltage-dependent sodium channels (Remy et al., 2004) as well as of the glutamate transporter EAAC1 (Xia et al., 2006) . One or several of these effects may be responsible for the reduced seizure threshold observed in SNC80-treated animals. Blocking of DOR with the specific antagonist naltrindole did not result in altered seizure behaviour in mouse and rat (Comer et al., 1993; Mazarati et al., 1999; Manocha et al., 2003) . Minor endogenous activation of DOR in the hippocampus is also supported by the low expression of proenkephalin in naive mice. In any case, the reduction in seizure threshold through pharmacological activation of DOR appears independent of the presence or absence of prodynorphin-derived peptides.
The effect of U-50488 was completely reversed by the KOR-specific antagonist GNTI, clearly indicating the predominance of KOR in the anti-ictal functions of endogenous prodynorphin-derived peptides. Our data rule out a significant contribution of MOR-mediated effects to the seizure regulation through dynorphin, although this receptor is expressed about 40% higher in Dyn À/À mice. Minor action of prodynorphin-derived peptides on DOR is suggested by the fact, that the seizure threshold of Dyn À/À mice treated with the KOR selective agonist U-50488 did not significantly differ from wild-type mice, although proconvulsant effects of dynorphin acting on DOR should be erased through prodynorphin knockout.
Although there is some evidence for anticonvulsant activity of dynorphin (for review see Solbrig and Koob, 2004) , one of the major open questions is the receptor mediating these effects. KOR density is rather low in the hippocampus, on the other hand their distribution is strategically perfect in terms of dampening excitation in the limbic circuitry. Indeed, KOR are also capable to block LTP in the hippocampus (Wagner et al., 1993) . Presynaptic KOR are located on terminals of perforant path fibres, mossy fibres and pyramidal neurons (Drake et al., 1994; Terman et al., 2000) . CA1 and CA3 neurons also contain KOR mRNA (Mansour et al., 1994) . Presynaptic KOR of perforant path fibres and mossy fibres, as well as postsynaptic KOR on CA3 pyramidal neurons are potential targets for dynorphin released from mossy fibres during seizures. Presynaptic activation of KOR decreases N-, L-and P/Q-type Ca þþ currents (Rusin et al., 1997) , resulting in reduction of glutamate release. Stimulation of voltage-gated K þ channels through postsynaptic KOR was proposed for pyramidal neurons (Moore et al., 1994; Madamba et al., 1999) . In sum these effects, together with other potentially anticonvulsant sites of KOR action like the thalamus or substantia nigra cause an $15% higher seizure threshold in wild-type mice as compared with Dyn À/À animals. Unfortunately, no data addressing seizure behaviour in KOR knockout mice are available by now.
The differences between the genotypes observed in the model of intrahippocampal KA injection are in agreement with the potential sites of action for dynorphin. Thus, the GCL displayed augmented dispersion and reduction of SST-ir interneurons was increased in the target area of mossy fibres, CA3. In general, SST-ir neurons were significantly more reduced in Dyn À/À mice, which might be related to higher release of glutamate, but also directly to the lack in dynorphin, as these SST/NPY neurons were reported to express KOR in rat (Racz and Halasy, 2002) . In any case, it should be kept in mind that reduced numbers of SST-ir cells does not necessarily reflect neuronal death, but may also reflect a decrease in SST levels below detection limit. Interestingly, no change in numbers of SST-ir cells was observed in the contralateral hilus, although there was a marked drop in Nissl-stained neurons. In addition, Dyn À/À mice also show significant loss of neurons in the contralateral hippocampal area CA1, potentially reflecting increased commissural excitatory signalling due to loss of dynorphin. Marked stimulation of the contralateral hippocampus in both groups of animals was indicated by the appearance of NPY immunoreactivity in mossy fibres of both hippocampi in all KA-treated animals. Taken together, the differences in neuropathology suggest a higher excitatory level of the limbic circuit in Dyn À/À mice. This is in line with other reports of the effects of opioids on hippocampal excitability (Wagner et al., 1993; Terman et al., 2000) .
Partial loss of control on excitatory neurotransmission through perforant path and mossy fibre synapses may well account also for the faster kindling observed in the Dyn À/À mice. Actually the kindling rate in Dyn À/À mice at 20 mg PTZ/kg is significantly faster than in wild-type littermates treated with 20 mg PTZ/kg, but comparable with that observed in wild-type mice treated with 25 mg PTZ/kg in dose-finding experiments (data not shown).
Also under debate is the finding of increased seizure susceptibility in humans with a prodynorphin gene promoter polymorphism resulting in reduced expression of prodynorphin (Stogmann et al., 2002) . Similar results were reported by Gambardella et al. (2003) . Although the specific associations reported by Stogmann et al. (2002) could not be reproduced in more recent studies (Cavalleri et al., 2005) , the authors state that the mutation in the prodynorphin promoter may act as a general risk factor for epilepsy. Noteworthy, only 50 patients out of 752 investigated in this study matched the phenotype investigated by Stogmann et al. (2002) . Our data support the findings of Stogmann et al. (2002) . On the other hand, the about 25% reduction in prodynorphin mRNA observed in heterozygous Dyn þ/À mice (data not shown) yield only a tendency to reduced seizure threshold. This might explain the difficulties to reproduce the observations of Stogmann and colleagues.
